1AI

0.00%

0.8¢ algorae pharmaceuticals limited

phase II Vs phase I, page-21

First 21 Last

Share
Profile

Follow
daybreaker

306 Posts.

24/10/17

22:03

Post #: 28163178
Share

Originally posted by whytee ↑

Problem is your table only gives a dose response curve from 0 (Placebo) to 120 (max) for the 18 "identical" patients. It is unlikely to be the case.

It gets more complicated as other variables which might influence response get taken into account such as duration and severity of the illness and dose and baseline response to L-dopa. The usual demographic data such as age and sex of the trial patients will also be included.

Then we have the single primary outcome and 7 secondary outcome measures. While the trial goes for 26 weeks, there might well have been multiple evaluations - in the first trial the patients were examined every 4 weeks. So a wealth of data could be generated which will need to be analysed.

The expectation would be that all of the patients (including the placebo ones) will show an initial improvement in the PDQ-39 Quality of Life scores, but this will decline in the placebo patients over the six months while being sustained in the treated patients. The placebo patients will not show any improvement in objective observed motor performance and may require an increase in medication, whereas the treated patients will show a steady improvement in motor performance over the six months and a reducing dose of medication. The improvement in response will possibly be faster and more complete in those patients with less severe disease to begin with, and a slower but still significant response in the more severely affected patients who initially were on more medication to begin with. Age and sex might not be significant factors when severity is taken into account. If data is available after the 26 weeks it will likely show continued, sustained improvements.

Honestly I am not sure how much effect bigger doses will have over six months. Neurones grow relatively slowly and probably LCT had some good reason to start with a dose of 40 based on their animal testing. But given that some of the implanted cells will probably die, more might be better so a reasonable position would be to guess that 80 will be better than 40 but 120 not much of an improvement over 80.

All just educated guess work on my part, but LCT are "eagerly awaiting the results...", so perhaps that indicates some confidence. I'm betting heavily that the result will be positive in all groups except the placebo patients, but there will be considerable variation in response of the treated patients according to the initial disease severity. The result will be clear however.

Expand

Personal opinion; a noticeable difference has been observed and coincides with the time when shares left the 13c gridlock. BOD anxious to grab more shares have little doubt where this is heading. Finding the sweet spot for treatment may not happen with this trial but hopefully indicative in a meaningful way.
Cheers

LCT Price at posting: 24.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

HLX

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

There are more pages in this discussion • 26 more messages in this thread...

First 21 Last

Add 1AI (ASX) to my watchlist

(20min delay)
Last 0.8¢		Change 0.000(0.00%)		Mkt cap ! $13.49M

Open	High	Low	Value	Volume
0.8¢	0.8¢	0.8¢	$291	36.35K

Buyers (Bids)

No.	Vol.	Price($)
3	243367	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	1778841	10

View Market Depth

No.	Vol.	Price($)
3	243367	0.008
12	4919787	0.007
10	4486749	0.006
6	2510009	0.005
4	4065000	0.004

Price($)	Vol.	No.
0.009	1778841	10
0.010	2702788	5
0.011	1490400	3
0.012	330000	2
0.014	170000	2

Last trade - 14.04pm 30/08/2024 (20 minute delay)

1AI (ASX) Chart

phase II Vs phase I, page-21

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Lendlease sells off US east coast construction operations in latest global divestment push

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

phase II Vs phase I, page-21

Top Stories

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Lendlease sells off US east coast construction operations in latest global divestment push

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News